Bristol Myers Squibb (BMY) Short term Debt (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Short term Debt for 18 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short term Debt fell 78.22% year-over-year to $1.0 billion in Q2 2026; TTM through Jun 2026 was $1.0 billion, a 78.22% decrease from a year earlier, with the FY2025 full-year figure at $2.3 billion, up 10.51% from the prior year.
• Short term Debt was $1.0 billion for Q2 2026 at Bristol Myers Squibb, down from $2.3 billion in the prior quarter.
• Over five years, Short term Debt peaked at $7.5 billion in Q1 2022 and troughed at $1.0 billion in Q2 2026.
• A 5-year average of $3.6 billion and a median of $3.3 billion in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt jumped 323.3% in 2022 and slumped 80.28% in 2024, its largest moves.
• Over 5 years, Short term Debt stood at $4.3 billion in 2022, then dropped by 26.85% to $3.1 billion in 2023, then slumped by 34.4% to $2.0 billion in 2024, then rose by 10.51% to $2.3 billion in 2025, then plunged by 54.58% to $1.0 billion in 2026.
• The last three Short term Debt figures came in at $1.0 billion (Q2 2026), $2.3 billion (Q1 2026), and $2.3 billion (Q4 2025), per Business Quant data.